

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

July 27, 2023

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers,
Dalal Street, Mumbai-400001
Script Id: 506365

Subject: Outcome of Board Meeting Held on Thursday, July 27, 2023

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. July 27, 2023, have discussed the following matters:

1. Approval of Un-Audited Financial Results of the Company for the quarter ended June 30, 2023 along with the Limited Review Report thereon.
2. Approval of the Notice of the 81st Annual General Meeting of the Company to be held on Monday, September 25, 2023 at 04:00 p.m. at the Registered Office of the Company at 5-Kumud Apartment Co. op. Hsg. Soc. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane- 421301 for the year ended March 31, 2023.
3. Approval of Book Closure date from September 19, 2023 to September 25, 2023 (both days inclusive) and Record Date will be September 18, 2023.
4. Appointment of CS Hemant Shetye, Designated Partner of HSPN & Associates LLP, Company Secretaries, to act as a Scrutinizer for the forthcoming 81st Annual General Meeting of the Company.

The Meeting commenced at 04.00 p.m. and concluded at 05.15 p.m.

Thanking You.

Yours Faithfully,

For CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN – 03063364)



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

| Sr. No. | Particulars | (Rupees in Thousand) | | | |
|---------|---|-----------------------------|----------------------------|-----------------------------|----------------------------|
| | | Quarter Ended | | | Year Ended |
| | | 30th June 2023 Unaudited | 31st March 2023 Audited | 30th June 2022 Unaudited | 31st March 2023 Audited |
| I | Revenue from Operations | | | | |
| II | Other Income | 4,294 | (971) | (3,847) | 2,951 |
| III | Total Revenue (I + II) | 4,294 | (971) | (3,847) | 2,951 |
| IV | Expenses | | | | |
| | (1) Cost Materials consumed | - | - | - | - |
| | (2) Purchase of Stock-in-Trade | - | - | - | - |
| | (3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade | - | - | - | - |
| | (4) Employee Benefits Expenses | 23 | - | 445 | 791 |
| | (5) Depreciation and Amortisation Expenses | 21 | 32 | 33 | 131 |
| | (6) Administrative and Other Expenses | 487 | 200 | 683 | 1,297 |
| | (7) Finance Costs | - | - | - | - |
| | Total Expenses | 531 | 232 | 1,160 | 2,219 |
| V | Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV) | 3,763 | (1,203) | (5,007) | 732 |
| VI | Exceptional Items | - | - | - | - |
| VII | Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI) | 3,763 | (1,203) | (5,007) | 732 |
| VIII | Extra Ordinary Items | - | - | - | - |
| IX | Profit/(Loss) before Tax (VII-VIII) | 3,763 | (1,203) | (5,007) | 732 |
| X | Tax Expenses | | | | |
| | (1) Current Tax | - | 114 | - | 114 |
| | (2) Tax Adjustment Previous Year | - | 1 | - | (18) |
| | (3) Deferred Tax Income | - | (1,045) | - | (1,045) |
| | (4) MAT Credit Entitlement | - | 1,207 | - | 1,207 |
| XI | Profit/(Loss) for the period from continuing operations (IX - X) | 3,763 | (1,480) | (5,007) | 473 |
| XII | Profit/(Loss) from discontinuing operations | - | - | - | - |
| XIII | Tax Expenses of discontinuing operations | - | - | - | - |
| XIV | Profit/(Loss) from discontinuing operations (after tax) (XII - XIII) | - | - | - | - |
| XV | Profit/(Loss) for the period (XI - XIV) | 3,763 | (1,480) | (5,007) | 473 |
| XVI | Other Comprehensive Income | | | | |
| | A (i) Items that will not be reclassified to profit or loss | | | | |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | | | | |
| | B (i) Items that will not be reclassified to profit or loss | | | | |
| | (ii) Income tax relating to items that will not be reclassified | - | - | - | - |
| XVII | Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period) | 3,763 | (1,480) | (5,007) | 473 |
| XVIII | Earnings per Share : | | | | |
| | (1) Basic | 2.51 | (0.99) | (3.34) | 0.32 |
| | (2) Diluted | | | | |

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The Company holds 18,100 equity shares of Allcargo Logistics Ltd. at fair value amounting to Rs.5,143,115 as at June 30, 2023. Allcargo Logistics Ltd. carried out the demerger of two of its divisions into two new companies and the shareholders received equity shares in the new companies in the ratio of 1:1. Accordingly, the Company received 18,100 shares in Allcargo Terminals Ltd. and Transindia Reality & Logistics Parks Ltd. each. As such, the investments have been recorded at their face values in the books and since both the demerged companies are yet to be listed on any stock exchange, fair valuation has not been considered in the unaudited financial results for the quarter ended June 30, 2023.



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

- 3 The above Standalone Unaudited Financial Results for the Quarter Ended 30.06.2023 have been reviewed by the Audit Committee in their Meeting held on 27.07.2023 and approved by the Board of Directors of its Meeting held on 27.07.2023. The Limited Review Report of Auditors M/s Sanjay Rane & Associates LLP was also taken on record by the Board in its Meeting.
- 4 The Company is not having any Subsidiary Company.
- 5 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited



Ashok Somani

Ashok Somani
Director

DIN : 03063364

Date : 27th July, 2023

Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. in Thousand)

| PARTICULARS | STANDALONE | | |
|--|--|--|-------------------------------------|
| | UNAUDITED QUARTER ENDED 30.06.2023 | UNAUDITED QUARTER ENDED 30.06.2022 | AUDITED YEAR ENDED 31.03.2023 |
| Reconciliation of Profit After Tax as reported earlier: | | | |
| Net Profit / (Loss) for the Period (as per AS) | | | |
| Benefit / (Charge): | | | |
| Impact of Deferred Income (Government Grant) Amortized to Income | - | - | - |
| Impact of Fair Valuation of Financial Instruments | - | - | - |
| Impact of Actuarial Gain / Loss Taken OCI | 2,778 | (4,923) | - |
| Impact of Adjustment of Deferred Tax | - | - | - |
| Impact of Adjustment of MAT Credit Entitlement | - | - | (1,045) |
| Net Profit / (Loss) for the Period (as per AS) | 3,763 | (5,007) | 473 |

For Chemo Pharma Laboratories Ltd.



Ashok Somani

Ashok Somani

Director

DIN : 03063364

Date : 27th July, 2023

Place : Mumbai

Sanjay Rane & Associates LLP

CHARTERED ACCOUNTANTS

Phone : +91 (22) 4919 8585
Email : admin@ssrane.net
Website : www.ssraneandco.com
LLP IN : ABZ-0863

LIMITED REVIEW REPORT

To,
Board of Directors of Chemo Pharma Laboratories Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of CHEMO PHARMA LABORATORIES LIMITED for the quarter ended June 30, 2023 and year to date results for the three months period from April 01, 2023 to June 30, 2023 ("the Statement").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates LLP
Chartered Accountants
Firm Reg. No. 121089W/W100878



CA. Abhijeet Deshmukh
Partner
Membership No. 129145



Date: July 21, 2023

Place: Mumbai

UDIN: 23129145BGQKLK4998